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Introduction {#sec001}
============

Marmoset wasting syndrome (MWS) is one of the leading causes of morbidity and mortality in captive marmosets \[[@pone.0234634.ref001]\]. The common clinical signs of MWS are chronic weight loss, diarrhea and anemia \[[@pone.0234634.ref002]\]. Although several different lesions have been pathologically found in marmosets with clinical signs of MWS \[[@pone.0234634.ref003], [@pone.0234634.ref004]\], chronic colitis is considered one of the most important contributing factors for the development of MWS \[[@pone.0234634.ref005]--[@pone.0234634.ref007]\]. Tranexamic acid and glucocorticoid are often used to treat symptoms \[[@pone.0234634.ref001], [@pone.0234634.ref008]\]. The other options, such as dietary manipulation and stress minimization, also may help reduce the risks of developing MWS \[[@pone.0234634.ref002]\]. However, there is no reliable treatment for MWS. There is also no definitive antemortem diagnosis method for MWS.

Polyunsaturated free fatty acids (PUFAs) are divided into omega-6 (*n*-6) and omega-3 (*n*-3) groups based on double bond positions. The *n*-6 PUFAs include linoleic acid (LA), dihomo-γ-linolenic acid (DGLA) and arachidonic acid (AA), whereas *n*-3 PUFAs include α-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Three types of oxygenases, cyclooxygenase (COX), lipoxygenase (LOX) and cytochrome P450 (CYP) epoxygenase oxidize PUFAs and convert to lipid mediators and/or their related metabolites \[[@pone.0234634.ref009]\].

Lipid mediators are bioactive molecules and have identified hundreds of different types in the mammalian body. It has been demonstrated that lipid mediators positively and/or negatively regulate inflammatory responses \[[@pone.0234634.ref010]\]. For example, AA-derived COX metabolite prostaglandin (PG) E~2~ (PGE~2~) induces arterial dilation and vascular hyper-permeability resulting in edema, which is a classic sign of inflammation \[[@pone.0234634.ref011]\]. Another AA-derived pro-inflammatory mediator leukotriene B~4~ induces chemotaxis and the production of pro-inflammatory cytokines in neutrophils \[[@pone.0234634.ref012], [@pone.0234634.ref013]\]. In contrast, the EPA-derived LOX metabolite resolvin exerts anti-inflammatory properties by inhibiting the recruitment of leukocytes and/or the production of pro-inflammatory cytokines \[[@pone.0234634.ref014]\].

Lipid mediators and their related metabolites are present in the urine and their levels change according to the host inflammatory condition. Indeed, some specific lipid metabolites positively correlate with disease activity score in human rheumatoid arthritis \[[@pone.0234634.ref015]\]. In addition, our previous study demonstrated that a major urinary metabolite of PGD~2~, tetranor-PGDM, positively correlates with the severity of food allergies in mice and humans \[[@pone.0234634.ref016]\]. Thus, the profiles of urinary lipid metabolites can be convenient indices of various types of diseases.

On the basis of these backgrounds, we performed an LC-MS-based comprehensive analysis of lipid metabolites in the urines of marmosets suffering from MWS to understand pathophysiological features and to provide some insight for the development of a diagnostic method.

Materials and methods {#sec002}
=====================

Humane care guidelines {#sec003}
----------------------

All procedures used in this study followed the Guidelines for the Care and Use of Nonhuman Primates, provided by Primate Research Institute, Kyoto University (KUPRI). The protocol for urinary sampling was approved by Institutional Animal Care and Use Committee in KUPRI (approval number: 2018--079). We did not anesthetize or euthanize animals for the purpose of this study. No specific animal research protocol was drafted for this study in the Jikei University School of Medicine (Jikei) and Marmoset Breeding Facility, CLEA Japan, Inc. study as only clinical samples were provided to the study.

Rearing conditions of marmosets {#sec004}
-------------------------------

The marmosets were housed in family cages (W700 x D700 x H1500 mm or W910 x D700 x H1600 mm in KUPRI, W800 x D650 x H1500 mm in Jikei), paired cages (W1200 x D600 x H1000 mm in KUPRI, W800 x D650 x H720 mm in Jikei.) or individual/intensive care cages (W600 x D600 x H1000 mm in KUPRI, W400 x D650 x H720 mm in Jikei, W390 x D550 x H700 mm in CLEA). The room temperature was kept at 28 ± 5°C. Water was available ad libitum. They were fed on 50 ml (20--30 g) pellet (SPS, Oriental Yeast Co. ltd., Tokyo, Japan) twice a day supplemented with apple and quail's egg three times a week, banana twice a week and occasional mealworm (the larva of Tenebrionidae) in KUPRI. In Jikei, they were fed on 40 g pellet (LabDiet, PMI Nutrition International LLC, U.S.A) twice a day supplemented with honey, Vitamin C and D. In CLEA, they were fed on 40--50 g CMS-1M (CLEA Japan, Inc., Tokyo, Japan) soaked in water and supplemented with Vitamin C and D once a day, and boiled eggs twice a week. Estimated concentrations of n-6 and n-3 PUFAs contained in diet were comparable in each institution or between healthy and MWS marmosets ([Table 1](#pone.0234634.t001){ref-type="table"}). In all institutions, environmental enrichment, including gum feeders, wooden toys, climbing structures and swings, was provided depending on the housing condition. The animal care staffs observed the health and well-being of the animals daily using criteria, such as fecal condition, appetite, hair condition and movement, and if they were suspected to have any problems, they would be evaluated by the veterinarians. After the study, control marmosets were used in different projects and MWS marmosets underwent further treatment.

10.1371/journal.pone.0234634.t001

###### The concentration of PUFAs contained in diet.

![](pone.0234634.t001){#pone.0234634.t001g}

                     PUFAs (g/100 g food)   KUPRI               Jikei         CLEA
  ------------------ ---------------------- ------------------- ------------- -------------
  n-6                Linoleic acid          4.16 (1.66--2.82)   3.12 (2.5)    4.70 (1.88)
  Arachidonic acid   N.D.                   0.04 (0.03)         N.D.          
  n-3                Linolenic acid         0.24 (0.10--0.32)   0.31 (0.25)   0.54 (0.21)
  DHA                0.11 (0.02--0.05)      0.35 (0.28)         0.04 (0.02)   
  EPA                0.08 (0.01--0.03)      0.02 (0.01)                       

The values in parentheses indicate the ingested concentration of PUFAs per day. KUPRI, Kyoto University Primate Research Institute; Jikei, The Jikei University School of Medicine; CLEA, Marmoset Breeding Facility, CLEA Japan, Inc.

Identification of MWS {#sec005}
---------------------

The major criteria of MWS were based on the previous report; recurrent diarrhea, absence of pathogenic enteric bacteria and endoparasites, resolution of illness despite anti parasitic treatment and/or antibiotics, and persistent weight loss \[[@pone.0234634.ref002]\]. The veterinarians in each institution assessed the animals prior to inclusion in the study. The information of each marmoset was shown in the [Table 2](#pone.0234634.t002){ref-type="table"}. In general, healthy adult marmosets weigh around 350 g in captivity \[[@pone.0234634.ref017]\]. In this study, the body weight of each healthy marmoset exceeded 300 g (except for No.4, which was 1 year old and still growing), however, that of marmosets with MWS were around or less than 300 g at urine samples collection. Frequent and recurrent diarrhea, and persistent weight loss for over six months were observed in marmosets with MWS. Marmosets with MWS had a history of medication, such as ursodeoxycholic acid and pancrelipase, but which had been taken approximately 1 month before urine samples collection.

10.1371/journal.pone.0234634.t002

###### Body weight and clinical signs in individual animals.

![](pone.0234634.t002){#pone.0234634.t002g}

                No.     Institution   Gender   Age (year)   Maximum BW (g)   BW (g)                                       Clinical signs
  ------------- ------- ------------- -------- ------------ ---------------- -------------------------------------------- ------------------------------------------------------
  **Healthy**   1       KUPRI         male     4            370              354                                          None
  2             KUPRI   male          6        384          378              None                                         
  3             Jikei   male          9        323          320              None                                         
  4             CLEA    female        1        290          290              None                                         
  5             CLEA    male          2        420          375              None                                         
  6             CLEA    male          1        340          335              None                                         
  7             CLEA    male          2        310          310              None                                         
  **MWS**       1       KUPRI         male     6            336              280                                          frequent, recurring diarrhea, persistent weight loss
  2             Jikei   male          4        350          193              persistent weight loss                       
  3             CLEA    male          3        265          240              recurring diarrhea, persistent weight loss   
  4             CLEA    male          9        350          225              recurring diarrhea, persistent weight loss   
  5             CLEA    male          6        345          300              recurring diarrhea, persistent weight loss   
  6             CLEA    female        7        340          290              recurring diarrhea, persistent weight loss   
  7             CLEA    female        5        340          215              recurring diarrhea, persistent weight loss   

KUPRI, Kyoto University Primate Research Institute; Jikei, The Jikei University School of Medicine; CLEA, Marmoset Breeding Facility, CLEA Japan, Inc.

Urine samples {#sec006}
-------------

The urine samples were collected from common marmosets (*Callithrix jacchus*) diagnosed as healthy (N = 7) in primary care or MWS (N = 7). Some of the control marmosets were in pair or family cages, while others were in individual cages for research or management purpose (not related to this study). MWS marmosets were in individual cages when their conditions were deteriorating and required intensive care \[[@pone.0234634.ref002]\]. When the marmoset was in a pair or family cage, the marmoset was temporarily separated from other individuals using separation wall to collect urine samples. In some occasions, even in a pair or family cage, when a marmoset was urinated in front of us, the urine sample was collected immediately. A clean dry tray was placed under the cage. All urine samples were collected only when visually confirmed not to be contaminated with feces, another individual's urine, or dropped food. After each sample collection, the trays were sterilized, rinsed thoroughly and dried. The urine samples were stored until use at -80°C.

Sample preparation {#sec007}
------------------

After the urine samples were centrifuged at 20,000 x *g* for 5 min, aliquot of 200 μl urine was mixed with 350 μl of 0.1% formic acid water and 50 μl of the internal standard solution. The mixed solutions were applied to solid phase extraction cartridge (OASIS μElution plate, Waters, Massachusetts, USA) preconditioned with 200 μl methanol and distilled water (DW). After washing with 200 μl DW and 200 μl hexane, lipids fractions were eluted with 100 μl methanol.

LC-MS-based comprehensive analysis of lipid metabolites {#sec008}
-------------------------------------------------------

The 5 μl sample solution was injected to high performance liquid chromatography (Nexera 2, Shimadzu, Kyoto, Japan) equipped with mass spectrometer (LCMS-8060, Shimadzu, Kyoto, Japan). 138 types of metabolites, 3 types of PUFAs and 15 types of internal standards were measured and analyzed by using LC/MSMS Method Package for Lipid Mediators version 2 with LabSolutions software (Shimadzu, Kyoto, Japan) as manufacturers instruction ([S1 Table](#pone.0234634.s001){ref-type="supplementary-material"}). Each metabolite was identified by retention time and selected reaction monitoring ion transition ([S1 Table](#pone.0234634.s001){ref-type="supplementary-material"}). The change of each metabolite level between healthy and MWS urines was examined by comparing the peak area ratio calculated as following formula; The peak area of each metabolite / the peak area of internal standard. Each value was further corrected by the concentration of creatinine measured by LabAssay^™^ Creatinine (Wako, Osaka, Japan).

Statistical analysis {#sec009}
--------------------

All data are shown as mean ± SEM. The statistical difference was determined by Mann-Whitney U test for two-group comparison. Statistically significance was determined when p-value is less than 0.05.

Results {#sec010}
=======

Detected lipid metabolites in the urines of MWS {#sec011}
-----------------------------------------------

We measured 141 types of lipid metabolites including 3 types of PUFAs (AA, EPA and DHA) using urine samples from healthy marmoset (N = 7) and marmosets with MWS (N = 7) ([Table 2](#pone.0234634.t002){ref-type="table"} and [S1 Table](#pone.0234634.s001){ref-type="supplementary-material"}). Marmosets in each institution were fed different food, but marmosets with heathy and MWS were fed the same food in each institution ([Table 1](#pone.0234634.t001){ref-type="table"}). In addition, to unveil the inflammatory features of MWS, we focused and analyzed the metabolites that were constantly detected in all MWS individuals. Under these criteria, we detected 3 types of PUFAs ([Fig 1](#pone.0234634.g001){ref-type="fig"}) and 38 types of metabolites in total (Figs [2](#pone.0234634.g002){ref-type="fig"}--[4](#pone.0234634.g004){ref-type="fig"}). In the detected 38 types of metabolites, *n*-6 PUFAs-derived metabolites accounted for 82% (31/38 types), on the other hand, the rest of metabolites were consisted of *n*-3 PUFAs-derived metabolites (7/38 types). Furthermore, AA-derived metabolites accounted for 66% (25/38 types) of total detected metabolites. The amount of AA tended to decrease but that EPA or DHA did not change in MWS urines compared to healthy urines ([Fig 1](#pone.0234634.g001){ref-type="fig"}). These results suggest that *n*-6 fatty acids, especially AA, are mainly consumed in MWS marmosets.

![The urinary level of PUFAs.\
The urinary levels of arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in healthy marmoset (N = 7) and marmosets with MWS (N = 7).](pone.0234634.g001){#pone.0234634.g001}

![The urinary levels of AA-derived enzymic-oxidative metabolites.\
The urinary levels of arachidonic acid (AA)-derived catalyzed metabolites in healthy marmoset (N = 7) and marmosets with MWS (N = 7). di. dihydro; te, tetranor; COX, Cyclooxygenase; CYP, cytochrome P450 epoxygenase; LOX, lipoxygenase. \*p\<0.05, \*\*p\<0.01 compared to healthy urines.](pone.0234634.g002){#pone.0234634.g002}

![The urinary levels of AA-derived isoprostanes.\
The urinary levels of arachidonic acid (AA)-derived isoprostanes produced by non-enzymatic oxidation in healthy marmoset (N = 7) and marmosets with MWS (N = 7). \*\*p\<0.01 compared to healthy urines.](pone.0234634.g003){#pone.0234634.g003}

![The urinary levels of lipid metabolites derived from PUFAs except AA.\
The urinary levels of (A) linoleic acid (LA), (B) dihomo-γ-linolenic acid (DGLA), (C) α-linoleic acid (ALA), (D) eicosapentaenoic acid (EPA) and (E) docosahexaenoic acid (DHA)-derived metabolite in healthy marmoset (N = 7) and marmosets with MWS (N = 7). \*p\<0.05 compared to healthy urines. LOX, lipoxygenase; COX, cyclooxygenase; CYP, cytochrome P450 epoxygenase.](pone.0234634.g004){#pone.0234634.g004}

Metabolic pathways of detected lipid metabolites {#sec012}
------------------------------------------------

The metabolic pathways of all detected metabolites were drawn in Figs [2](#pone.0234634.g002){ref-type="fig"}, [3](#pone.0234634.g003){ref-type="fig"} and [4](#pone.0234634.g004){ref-type="fig"}. To determine which lipid mediators are critically involved in the development of MWS, we focused on the lipid metabolites that significantly increased in the urines of MWS than that of healthy marmosets. As shown in [Fig 2](#pone.0234634.g002){ref-type="fig"}, the major AA metabolites, PGE~2~, PGF~2α~ and its metabolite of 13, 14-dihydro-15-keto-tetranor-PGF~2α~ and a metabolite of TXA~2~, TXB~2~ were detected at significant higher levels in the urines of MWS than that of healthy marmosets. These results suggest that those three types of mediators may play important roles in the development and progression of MWS ([Fig 2](#pone.0234634.g002){ref-type="fig"}).

Isoprostanes are non-enzymatic oxidative products of PUFAs. F~2~-isprostanes (F~2~-isoPs) are prostaglandin F~2~-like isoprostanes generated from AA. In this study, 5 types of F~2~-isoPs were detected and 4 types of that were significantly increased in MWS urines ([Fig 3](#pone.0234634.g003){ref-type="fig"}). Several studies reported that the amount of F~2~-isoPs were elevated under oxidative stress upon inflammation \[[@pone.0234634.ref018], [@pone.0234634.ref019]\]. Thus, detection of these F~2~-isoPs in urine may evidence the presence of inflammation associated oxidative stress in MWS.

In addition, DGLA-derived F~1~-isoprostane (F~1~-IsoP), 8-iso-PGE~1~, also significantly increased in the urine samples of MWS ([Fig 4](#pone.0234634.g004){ref-type="fig"}). The other PUFAs-derived urinary metabolites did not change between healthy and MWS group ([Fig 4](#pone.0234634.g004){ref-type="fig"}). It is reported that F~1~-IsoPs also produced by oxidative stress, however, the usefulness of urinary F~1~-IsoP as biomarker has not yet been reported. 8-iso-PGE~1~ may be a unique metabolite increased in MWS urine.

Discussion {#sec013}
==========

Several stimuli immediately activate appropriate oxidases, such as COX and LOX, and lead *de novo* synthesis of lipid mediators from *n*-6 and/or *n*-3 PUFAs. Generally, *n*-6 PUFA AA-derived lipid mediators accelerate inflammation pathways in both the acute and chronic phases. On the other hand, *n*-3 PUFAs EPA- and DHA-derived mediators accelerate the resolution of inflammation at the chronic phase \[[@pone.0234634.ref020], [@pone.0234634.ref021]\]. Thus, the number, types, and levels of lipid mediators are changed according to the severity and/or duration of inflammation. The urinary lipid profiling reflects these changes in host inflammatory condition as the dynamic balance between *n*-6 and *n*-3 PUFAs-derived metabolites. In the present study, *n*-6 PUFA, especially AA, -derived metabolites accounted for a majority of urinary lipid metabolites in marmosets with MWS. These results may reflect that MWS marmosets may have persistent inflammation accompanied by AA consumption.

Even though PGE~2~ and PGF~2α~ are highly metabolically unstable, these compounds were detected in the urines of marmoset. In addition to PGE~2~ and PGF~2α~, primary metabolites of these PGs in plasma, 13,14-dihydro-15-keto derivatives, were increased in the urines of marmosets with MWS. \[[@pone.0234634.ref022]\]. Thus, a large amount of these PGs would be produced in the inflammatory lesions and excreted into the MWS urines. However, previous studies have shown that some of the urinary PGE~2~ or PGF~2α~ are formed by free-radical catalyzed oxidation pathway (IsoP pathway) in the rodent and human \[[@pone.0234634.ref023], [@pone.0234634.ref024]\]. It cannot be ignored the possibility that urinary PGE~2~ and/or PGF~2α~ were generated by IsoP pathway and the increase of their levels reflect a free radical production by oxidative stress.

Chronic enteritis is a major post-mortal pathological feature of MWS \[[@pone.0234634.ref005]--[@pone.0234634.ref007]\]. We have also found many cases with severe chronic enteritis in marmosets clinically diagnosed with MWS in the colony at the KUPRI. In the present study, we found that the amounts of PGE~2~, PGF~2α~ and a metabolite or TXA~2~ were markedly increased in the urines of marmosets with MWS. Clinical studies have shown that PGE~2~ levels are elevated in the urine of patients with intestinal inflammation \[[@pone.0234634.ref025]\]. Gene deficiency or pharmacological blocking of the PGE~2~ receptor, EP4, ameliorated dextran sodium sulfate--induced colitis in mice \[[@pone.0234634.ref026]\]. Collins D et al. showed in an *in vitro* study that PGF~2α~ promoted chloride secretion in human colonic epithelial cells through a cAMP-mediated mechanism \[[@pone.0234634.ref027]\]. Further, TXA~2~ up-regulates neutrophil elastase release and aggravate trinitrobenzene sulfonic acid-induced guinea-pig colitis \[[@pone.0234634.ref028]\]. Our findings and those reports suggest that PGE~2~, PGF~2α~ and TXA~2~ may play important roles in the development and progression of MWS. Further investigations are needed to reveal the functional relevance of these mediators in MWS.

In this study, we found that F~2~-IsoPs were increased in the urine samples of marmosets with MWS. It is well known that the levels of urinary F~2~-IsoPs elevated in the presence of oxidative stress. Indeed, urinary levels of F~2~-isoP is elevated in the patients with Chron's diseases \[[@pone.0234634.ref029]\]. Considering that isoprostanes are chemically stable, urinary F~2~-IsoPs may be urinary biomarker of MWS. In addition to F~2~-IsoPs, we also found the increased level of F~1~-isoP, 8-iso PGF~1α~, which possibly be unique in MWS urine samples. To demonstrate the relevance of the urinary levels of F~2~-isoPs and F~1~-IsoP to the onset of MWS may be able to establish a new early diagnosis method for MWS.

The *n*-3 PUFAs are essential fatty acids that are identified as anti-inflammatory modulators by inhibiting AA metabolism and/or producing mediators, such as resolvin, lipoxin and protectin \[[@pone.0234634.ref030]\]. The decreased levels of *n*-3 PUFAs were reported in patients with inflammatory bowel disease. In this study, only 5 types of *n*-3 PUFAs-derived metabolites were constantly detected in the urine samples of marmosets with MWS. Additionally, the levels of *n*-3 PUFAs did not change in both groups. These results raised the possibility that *n*-3 PUFAs are not metabolized in MWS marmoset. Several reports have suggested that supplementation with *n*-3 PUFAs improved inflammation, including inflammatory bowel disease \[[@pone.0234634.ref031], [@pone.0234634.ref032]\]. The feeding of *n*-3 PUFAs containing food may be effective for the treatment of MWS.

To our knowledge, this is the first study assessing the urinary lipid profile of MWS. We found some lipid metabolites which may be involved in the development of MWS. Since MWS is a multifactorial disease and the cause of it remains unclear, we need further investigation to reveal a causal relationship. We believe our findings may provide some insight into understanding the mechanisms of development of MWS.

Supporting information {#sec014}
======================

###### Measured 141 types of lipid metabolites and 15 types of internal standards.
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Reviewer \#1: Yes

Reviewer \#2: No

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This work deals with PUFA selected metabolites in Marmosets suffering MWS. Because the cause is still unknown the subject should be deemed quite interesting. By comparison to the attached comments to the previous reviews I find the work almost acceptable for PLoS ONE. Unfortunately, we still do not know what is the real cause of MWS but the authors provided some mediators and mechanism for the development of that illness.

Some minor remarks:

\- Please add clearly in the conclusion that the cause of MWS remains unknown but the paper revealed some mechanisms and mediators of MWS

\- Lines 79-83: the authors provide information about different types of cages used in the experiment. Please make it clear for the reader when and why such cages were used. I suppose that an individual cage is ideal for urine sampling. If another cages were used, how the urine was sampled? Add appropriate info sentence.

Reviewer \#2: Thank you for your interest in MWS, not enough researches are focused on this to find a solution.

As much as I enjoyed your paper, I have a number of reservations that need to be addressed before I can recommend it for publishing. Find the notes added to the manuscript for details.

In large:

1\) Diarrhoea itself does not equal MWS. You need to add a section on how you identified MWS. From the read of your paper, it sounds like you can\'t say you were looking at MWS but maybe focus on inflammation or chronic diarrhoea. If they do have MWS maybe you can present weight loss data.

2\) You could do a better literature search, recent papers on MWS have not been included - see text for reference.

3\) Can you give us the nutrient concentrations of their diet? How much AA, DHA and EPA are they actually ingesting?

4\) as it stands, all your results support is that there is inflammation in animals with diarrhoea. You need the diet information to link with AA. If they eat the same diet and same amount of fatty acids, then causation will be somewhere else. You need the diet information to tie this all together, or change the scope of your paper to inflammation and darrhoea.

Reviewer \#3: I commend the author\'s efforts to try and shed light on to disease like WMS which remains a mystery even after so many attempts, however I do think there are some major flaws in the design. I do understand that sample sizes can be challenging but in a prevalent colony as described by the owners, a n of 7 for both groups do significantly limit the conclusions that can be drawn.

The title says production profile - I would remove production.

I do think there are many authors, actually more authors than study subjects and it would be good to know if they satisfied the criteria for authorship.

Ln24: It is a syndrome and hence more symptoms are needed to justify the syndrome.

Ln 34: I do not think given the low number of subjects, a substantial conclusion can be got from this.

Ln 42: I do think it is redundant to have steroid and glucocorticoids in the same line

Ln 72: Sampling method should be elaborated. LN 104; Were there liners? How did you clean them in between. If feces and urine fall on the same surface,how does one confirm there is no residual effect of the feces. How do you know these inflammatory lipids were not from a biofilm on the floor? The trays needs to be described?

ln 84 onwards: Diet is a huge component of serum and urine lipid profiles. They should have looked at animals on the same diet to see how they compared.

Ln 104: Urines should be replaced with urine samples. What was the duration between voiding and urine collection and storage. Volatile lipids can potentially be lost.Marmosets in certain facilities are trained to urinate, was an attempt for this made

LN 111 onwards:What was the normalization technique used?Was the quantity of metabolites normalized to USG or creatinine.

There should also be some way to look into if there was active sediment or not, or at least clinical signs or something to substantiate that these mediators were not produced within the urinary tract as a result of inflammation or infection. WMS is syndrome and hence this is important.

ln 146: This is an over stretch and this conclusion is not substantiated.

I do agree with the other reviewers that the CV and the study design and conclusions have severe limitations,this along with small number of marmosets make me question the validity of these findings. While I do understand how difficult it is to work with marmosets, and samples can be scarce, I do not think the current study can be published as isin good faith.Sorry

182- urines should be replaced with urine samples.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Francis Cabana, PhD

Reviewer \#3: Yes: Joseph Cyrus Parambeth

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

###### 

Submitted filename: PONE-D-20-02190_reviewerFC.pdf

###### 

Click here for additional data file.

10.1371/journal.pone.0234634.r003

Author response to Decision Letter 0

18 Apr 2020

The production profile of lipid metabolites in urine of marmoset wasting syndrome.

Review Comments to the Author

Reviewer \#1: This work deals with PUFA selected metabolites in Marmosets suffering MWS. Because the cause is still unknown the subject should be deemed quite interesting. By comparison to the attached comments to the previous reviews I find the work almost acceptable for PLoS ONE. Unfortunately, we still do not know what is the real cause of MWS but the authors provided some mediators and mechanism for the development of that illness.

Comment 1: Please add clearly in the conclusion that the cause of MWS remains unknown but the paper revealed some mechanisms and mediators of MWS

\<Response\>

As the reviewer suggested, we added the descriptions in Abstract and manuscript in line 257 as following; Abstract; "In this study, we found some urinary lipid metabolites suspected to be involved in the development of MWS. Although the cause of MWS remains unclear, our findings may provide some insight into understanding the mechanisms of development of MWS."

line 257; "We found some lipid metabolites which may be involved in the development of MWS. Since MWS is multifactorial disease and the cause of it remains unclear, we need further investigation to reveal a causal relationship. We believe our findings may provide some insight into understanding the mechanisms of development of MWS."

Comment 2: Lines 79-83: the authors provide information about different types of cages used in the experiment. Please make it clear for the reader when and why such cages were used. I suppose that an individual cage is ideal for urine sampling. If another cages were used, how the urine was sampled? Add appropriate info sentence.

\<Response\>

Some of the control marmosets were in pair or family cages, while others were in individual cages for research or management purpose (not related to this study). MWS marmosets were in individual cages when their conditions were deteriorating and required intensive care. When the marmoset was in a pair or family cage, the marmoset was temporarily separated from other individuals using separation wall to collect urine samples. In some occasions, even in a pair or family cage, when a marmoset was urinated in front of us, the urine sample was collected immediately. A clean dry tray was placed under the cage. All urine samples were collected only when visually confirmed not to be contaminated with feces, another individual's urine, or dropped food. After each sample collection, the trays were sterilized, rinsed thoroughly and dried. The urine samples were stored until use at -80°C. We added the descriptions in Methods "Urine Samples" section in line 116.

Reviewer \#2: Thank you for your interest in MWS, not enough researches are focused on this to find a solution. As much as I enjoyed your paper, I have a number of reservations that need to be addressed before I can recommend it for publishing. Find the notes added to the manuscript for details.

Comment 1: Diarrhea itself does not equal MWS. You need to add a section on how you identified MWS. From the read of your paper, it sounds like you can\'t say you were looking at MWS but maybe focus on inflammation or chronic diarrhea. If they do have MWS maybe you can present weight loss data.

\<Response\>

We identified MWS by the major criteria based on Cabana et al 2018; recurrent diarrhea, absence of pathogenic enteric bacteria and endoparasites, resolution of illness despite anti parasitic treatment and/or antibiotics, and persistent weight loss. The veterinarians in each institution assessed the animals and included in this study. All individuals with MWS had persistent weight loss for over six months. We added the descriptions in "Identification of MWS" in Methods section and the maximum body weight in Table 2.

Comment 2: You could do a better literature search, recent papers on MWS have not been included see text for reference.

\<Response\> We added the paper "Francis Cabana et al., Zoo Biol, 37 (2), 98-106. 2018." in line 40, 43, 103, and 118.

Comment 3: Can you give us the nutrient concentrations of their diet? How much AA, DHA and EPA are they actually ingesting? As it stands, all your results support is that there is inflammation in animals with diarrhea. You need the diet information to link with AA. If they eat the same diet and same amount of fatty acids, then causation will be somewhere else. You need the diet information to tie this all together or change the scope of your paper to inflammation and diarrhea.

\<Response\>

We newly added below table as Table 1, describing the concentration of each PUFAs contained in diet. As shown in table, sum of the concentration of n-6 and n-3 PUFAs were comparable in each diet fed marmoset in three institutions. In addition, we fed the same diet to healthy and MWS marmoset in each institution. Thus, the changes in urinary lipid profiles may reflect some inflammation but not the variation of the concentration of PUFAs derived from diet. We added Table 1 and related descriptions in line 90-92 and 161-162.

PUFAs (g/100 g food) KUPRI Jikei CLEA

n-6 Linoleic acid 4.16 (1.66-2.82) 3.12 (2.5) 4.70 (1.88)

Arachidonic acid N.D. 0.04 (0.03) N.D.

n-3 Linolenic acid 0.24 (0.10-0.32) 0.31 (0.25) 0.54 (0.21)

DHA 0.11 (0.02-0.05) 0.35 (0.28) 0.04 (0.02)

EPA 0.08 (0.01-0.03) 0.02 (0.01)

Reviewer \#3: I commend the author\'s efforts to try and shed light on to disease like WMS which remains a mystery even after so many attempts, however I do think there are some major flaws in the design. I do understand that sample sizes can be challenging but in a prevalent colony as described by the owners, a n of 7 for both groups do significantly limit the conclusions that can be drawn. The title says production profile - I would remove production. I do think there are many authors, actually more authors than study subjects and it would be good to know if they satisfied the criteria for authorship.

\<Response\>

This study was the first trial of focusing on lipid metabolism in MWS marmosets. We understood the limitation of this study by small sample size so that we do not try to conclude the cause of MWS. But instead, we proposed the possibility of the importance of AA in MWS. We believe that it is important to shed light on MWS from various aspects.

As reviewer suggested we removed the "production" from title. And some author did not satisfy the criteria for authorship, their name is listed in Acknowledgement.

Comment 1: Ln24: It is a syndrome and hence more symptoms are needed to justify the syndrome.

\<Response\>

We added the maximum weight of each marmoset in Table 2. Indeed, they all had persistent weight loss for over six months. We added the section on Identification of MWS in line 102 Methods Urine Samples.

Comment 2: Ln 34: I do not think given the low number of subjects, a substantial conclusion can be got from this.

\<Response\>

We understand the limitation of this study by small sample size. We added the descriptions indicating that we did not reveal the mechanisms of MWS in this study as in Abstract and line 257 as following.

Abstract; "In this study, we found some urinary lipid metabolites suspected to be involved in the development of MWS. Although the cause of MWS remains unclear, our findings may provide some insight into understanding the mechanisms of development of MWS." line 257; "We found some lipid metabolites which may be involved in the development of MWS. Since MWS is multifactorial disease and the cause of it remains unclear, we need further investigation to reveal a causal relationship. We believe our findings may provide some insight into understanding the mechanisms of development of MWS."

Comment 3: Ln 42: I do think it is redundant to have steroid and glucocorticoids in the same line

\<Response\>

We deleted the "steroid" in line 42.

Comment 4: Ln 72: Sampling method should be elaborated. LN 104; Were there liners? How did you clean them in between. If feces and urine fall on the same surface, how does one confirm there is no residual effect of the feces. How do you know these inflammatory lipids were not from a biofilm on the floor? The trays need to be described?

\<Response\>

As we described above as response to the reviewer \#1 comment 2, some of the control marmosets were in pair or family cages, while others were in individual cages for research or management purpose (not related to this study). MWS marmosets were in individual cages when their conditions were deteriorating and required intensive care. When the marmoset was in a pair or family cage, the marmoset was temporarily separated from other individuals using separation wall to collect urine samples. In some occasions, even in a pair or family cage, when a marmoset was urinated in front of us, the urine sample was collected immediately. A clean dry tray was placed under the cage. All urine samples were collected only when visually confirmed not to be contaminated with feces, another individual's urine, or dropped food. After each sample collection, the trays were sterilized, rinsed thoroughly and dried. The urine samples were stored until use at -80°C. We added the descriptions in line 116.

Comment 5: Ln 84 onwards: Diet is a huge component of serum and urine lipid profiles. They should have looked at animals on the same diet to see how they compared.

\<Response\> We newly added below table as Table 1, describing the concentration of each PUFAs contained in diet. As shown in table, sum of the concentration of n-6 and n-3 PUFAs were comparable in each diet fed marmoset in three institutions. In addition, we fed the same diet to healthy and MWS marmoset in each institution. Thus, the changes in urinary lipid profiles may reflect some inflammation but not the variation of the concentration of PUFAs derived from diet. We added Table 1 and related description in line 90-92 and 161-162.

PUFAs (g/100 g food) KUPRI Jikei CLEA

n-6 Linoleic acid 4.16 (1.66-2.82) 3.12 (2.5) 4.70 (1.88)

Arachidonic acid N.D. 0.04 (0.03) N.D.

n-3 Linolenic acid 0.24 (0.10-0.32) 0.31 (0.25) 0.54 (0.21)

DHA 0.11 (0.02-0.05) 0.35 (0.28) 0.04 (0.02)

EPA 0.08 (0.01-0.03) 0.02 (0.01)

Comment 6: Ln 104: Urines should be replaced with urine samples.

We revised. Thank you.

Comment 7: Ln 104: What was the duration between voiding and urine collection and storage. Volatile lipids can potentially be lost. Marmosets in certain facilities are trained to urinate, was an attempt for this made.

\<Response\>

Thank you for your advices. As descried in Response 4, the urine samples were collected as soon as they were found and only when they were not contaminated with feces, urine or dropped food. And then, the urine samples were stored until use at -80°C. We revised Methods Urine samples section in line 116.

Comment 8: Ln 111 onwards: What was the normalization technique used? Was the quantity of metabolites normalized to USG or creatinine. There should also be some way to look into if there was active sediment or not, or at least clinical signs or something to substantiate that these mediators were not produced within the urinary tract as a result of inflammation or infection. WMS is syndrome and hence this is important.

\<Response\>

We corrected the vales of lipid metabolites by creatinine concentration as described in line 149. Before the collection, we confirmed MWS based on the criteria (Cabana et al 2018) including the absence of pathogenic enteric bacteria and endoparasites.

Comment 9: ln 146: This is an over stretch and this conclusion is not substantiated. I do agree with the other reviewers that the CV and the study design and conclusions have severe limitations, this along with small number of marmosets make me question the validity of these findings. While I do understand how difficult it is to work with marmosets, and samples can be scarce, I do not think the current study can be published as is in good faith. Sorry.

\<Response\>

We understood the limitation of this study with sample size. This study was the first trial of focusing on lipid metabolism in MWS marmosets. We do not try to conclude that this is the cause of MWS, but instead, we proposed the possibility of the importance of AA in MWS. As described in Response to comment 4, we added the descriptions in Abstract and line 257.

Comment 10: 182- urines should be replaced with urine samples.

\<Response\>

We revised. Thank you.

###### 

Submitted filename: 20200417 Response to reviewers.docx

###### 

Click here for additional data file.
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5 May 2020

PONE-D-20-02190R1

The profile of lipid metabolites in urine of marmoset with wasting syndrome

PLOS ONE

Dear Prof. Murata,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Jun 19 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Petr Heneberg

Academic Editor

PLOS ONE

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In my opinion the authors improved the text according to the questions raised by the reviewers. It is acceptable for publication.

Reviewer \#3: Good job on the revisions. Thank you.

I do thing this needs some language editing and proof checking.

Please check the manuscript for language errors.

\- 45 MWS. There is also no definitive diagnosis method for MWS.

insert \'antemortem\'

89 Vitamin D. In CLEA, they were fed on 40-50 g CMS-1M (CLEA japan,

\- J should be uppercase in Japan

95 such as fecal condition, appetite, hair condition and movement, and if they were suspected \*any

96 problems, they would be \*\*consulted with veterinarians.

\- Add \*to have, \*\* evaluated by the veterinarian

105 and/or antibiotics, and persistent weight loss \[2\]. The veterinarians in each institution assessed the

106 animals and \*included in this study.

-\*Prior to inclusion in the study

157 We comprehensively measured

\- delete comprehensively

257 \*multifactorial disease and the cause of it remains unclear,

\- please add a

In all of the below line numbers, I do think they should say, marmosets with MWS, rather than MWS

109 however, that of MWS were around or less than 300 g at urine samples collection. Frequent and

110 recurrent diarrhea, and persistent weight loss for over six months were observed in MWS

116 as healthy (N = 7) in primary care or MWS (N = 7).

172 acid (DHA) in heathy (N = 7) and MWS (N = 7)

175 The urinary levels of arachidonic acid (AA)-derived catalyzed metabolites in heathy (N = 7) and

176 MWS (N = 7). di. dihydro; te, tetranor; COX, Cyclooxygenase; CYP, CYP450 epoxygenase; LOX,

177 lipoxygenase. \*p\<0.05, \*\*p\<0.01 compared to healthy urines.

180 The urinary levels of arachidonic acid (AA)-derived isoprostanes produced by non-enzymatic

181 oxidation in healthy (N = 7) and MWS (N = 7). \*\*p\<0.01 compared to healthy urines.

186 metabolite in healthy (N = 7) and MWS (N = 7). \*p\<0.05 compared to healthy urines. LOX,

187 lipoxygenase; COX, cyclooxygenase; CYP, cytochrome P450.

218 urinary lipid metabolites in MWS. These results may reflect that MWS marmosets may have

222 in plasma, 13,14-dihydro-15-keto derivatives, were increased in the urines of MWS \[22\]

231 amounts of PGE2, PGF2α and a metabolite or TXA2 were markedly increased in the urines of MWS.

234 ameliorated dextran sodium sulfate--induced colitis in mice \[26\]. Collins D et al. showed in an in vitro

240 In this study, we found that F2-IsoPs were increased in the MWS urine samples

250 this study, only 5 types of n-3 PUFAs-derived metabolites were constantly detected in MWS urines

The abstract has many language errors

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Jerzy Juskiewicz

Reviewer \#3: Yes: Joseph Cyrus Parambeth

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234634.r005

Author response to Decision Letter 1

28 May 2020

The production profile of lipid metabolites in urine of marmoset wasting syndrome.

Review Comments to the Author

Reviewer \#1: In my opinion the authors improved the text according to the questions raised by the reviewers. It is acceptable for publication.

\<Comments\>

Thank you very much for your time and suggestions.

Reviewer \#3: Good job on the revisions. Thank you. I do thing this needs some language editing and proof checking. Please check the manuscript for language errors.

\<Comments\>

Line 45 MWS. There is also no definitive diagnosis method for MWS. insert \'antemortem\'

Line 89 Vitamin D. In CLEA, they were fed on 40-50 g CMS-1M (CLEA japan, - J should be uppercase in Japan

Line 95-96 such as fecal condition, appetite, hair condition and movement, and if they were suspected \*any problems, they would be \*\*consulted with veterinarians. - Add \*to have, \*\* evaluated by the veterinarian

Line 105-106 and/or antibiotics, and persistent weight loss \[2\]. The veterinarians in each institution assessed the animals and \*included in this study. - \*Prior to inclusion in the study

Line 157 We comprehensively measured - delete comprehensively

Line 257 \*multifactorial disease and the cause of it remains unclear, - please add a

In all of the below line numbers, I do think they should say, marmosets with MWS, rather than MWS

Line 109 however, that of MWS were around or less than 300 g at urine samples collection. Frequent and recurrent diarrhea, and persistent weight loss for over six months were observed in MWS

Line 116 as healthy (N = 7) in primary care or MWS (N = 7).

Line 172 acid (DHA) in heathy (N = 7) and MWS (N = 7)

Line 175 The urinary levels of arachidonic acid (AA)-derived catalyzed metabolites in heathy (N = 7) and MWS (N = 7). di. dihydro; te, tetranor; COX, Cyclooxygenase; CYP, CYP450 epoxygenase; LOX, lipoxygenase. \*p\<0.05, \*\*p\<0.01 compared to healthy urines.

Line 180 The urinary levels of arachidonic acid (AA)-derived isoprostanes produced by non-enzymatic oxidation in healthy (N = 7) and MWS (N = 7). \*\*p\<0.01 compared to healthy urines.

Line 186 metabolite in healthy (N = 7) and MWS (N = 7). \*p\<0.05 compared to healthy urines. LOX, lipoxygenase; COX, cyclooxygenase; CYP, cytochrome P450.

Line 218 urinary lipid metabolites in MWS. These results may reflect that MWS marmosets may have

Line 222 in plasma, 13,14-dihydro-15-keto derivatives, were increased in the urines of MWS \[22\]

Line 231 amounts of PGE2, PGF2α and a metabolite or TXA2 were markedly increased in the urines of MWS.

Line 234 ameliorated dextran sodium sulfate--induced colitis in mice \[26\]. Collins D et al. showed in an in vitro

Line 240 In this study, we found that F2-IsoPs were increased in the MWS urine samples

Line 250 this study, only 5 types of n-3 PUFAs-derived metabolites were constantly detected in MWS urines

The abstract has many language errors

\<Responses\>

Thank you for your kind checking our language errors. We carefully revised the errors thoroughly manuscript including abstract.
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